Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Myelomatosis therapy trial for patients of all age groups.

Trial Profile

Myelomatosis therapy trial for patients of all age groups.

Phase of Trial: Phase III

Latest Information Update: 03 Sep 2015

At a glance

  • Drugs Thalidomide (Primary) ; Thalidomide (Primary) ; Antineoplastics; Clodronic acid; Cyclophosphamide; Dexamethasone; Doxorubicin; Melphalan; Prednisolone; Prednisone; Vincristine; Zoledronic acid
  • Indications Graft-versus-host disease; Multiple myeloma; Osteolysis
  • Focus Therapeutic Use
  • Acronyms MRC-Myeloma-IX; Myeloma-IX
  • Most Recent Events

    • 16 Jan 2014 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network
    • 10 Dec 2012 Results of thalidomide maintenance according to biological risk groups presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
    • 17 Jun 2012 Long-term follow-up results for the zolendronic acid versus clodronic acid randomisation presented at the 17th Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top